出版：MarketsandMarkets（マーケッツアンドマーケッツ） 出版年月：2023年11月
Respiratory Diagnostics Market – Global Forecast to 2029
呼吸器診断市場 : 製品とサービス (デバイス、試薬、ソフトウェア)、検査 (PFT、ピークフロー、スパイロメトリー)、OSA、イメージング (X 線、CT、MRI、PET)、分子 (PCR、DNA シーケンス)、適応症 (肺がん、喘息) 、COPD、TB) – 2029年までの世界予測
Respiratory Diagnostics Market by Product & Services (Devices, Reagents, Software), Test (PFT, Peak Flow, Spirometry), OSA, Imaging (X-ray, CT, MRI, PET), Molecular (PCR, DNA Sequencing), Indication (Lung Cancer, Asthma, COPD, TB) – Global Forecast to 2029
| ページ数 | 338 |
| 図表数 | 368 |
| 種別 | 英文調査報告書 |
| 価格 |
Report Overview
The global respiratory diagnostics market is projected to reach USD 8.2 billion by 2029 from USD 5.6 billion in 2023, at a CAGR of 6.6% during the forecast period. The growth of the respiratory diagnostics market is propelled by a combination of factors that collectively address the increasing global burden of respiratory diseases. Technological advancements, particularly in diagnostic tools and imaging techniques, have greatly improved the precision and efficiency of respiratory diagnostics, allowing for early detection and more effective management of conditions like COPD, TB, and lung cancer etc. Rising awareness among healthcare professionals and the public about the importance of early diagnosis, coupled with government-led screening programs, has contributed to a higher demand for respiratory diagnostic tests. The emergence of the COVID-19 pandemic has added a new dimension to the market, emphasizing the urgency of rapid and accurate diagnostics for respiratory infections. Changes in regulations, such as new requirements for product approval, labeling, or quality standards, can restrain the market growth.
“Instruments and Devices segment accounted for the largest share and is expected to grow at the highest rate during the forecast period.”
Due to the continuous advancements in diagnostic technologies, including imaging devices, spirometers, and other respiratory diagnostic instruments. Additionally, the increasing prevalence of respiratory diseases worldwide has driven the demand for sophisticated and accurate diagnostic tools, amplifying the significance of this segment. Innovations in point-of-care testing devices and portable diagnostic instruments have further fueled the growth of the Instruments and Devices segment, enabling healthcare professionals to conduct rapid and precise respiratory assessments. Hence, the aforementioned factors are driving the growth of the respiratory diagnostics market.
“The Mechanical tests segment accounted for the largest share and is expected to grow at the highest rate during the forecast period.”
Mechanical tests encompass a range of diagnostic tools, such as spirometers and peak flow meters, which play a significant role in evaluating lung capacity and airflow. The growing prevalence of respiratory disorders, coupled with the need for accurate diagnosis and monitoring, has propelled the demand for mechanical tests. Additionally, advancements in technology have enhanced the efficiency and accuracy of these tests, further driving their widespread adoption. Increasing demand for precise and comprehensive mechanical assessments of respiratory function will drive the growth of the respiratory diagnostics market.
“Asthma segment accounted for the largest share of the global respiratory diagnostics market.”
The rise in environmental pollutants, changing lifestyles, and genetic factors contribute to the growing incidence of asthma, necessitating advanced diagnostic solutions. The Asthma segment encompasses a range of diagnostic modalities, including pulmonary function tests, imaging techniques, and biomarker assessments, providing a comprehensive approach to asthma diagnosis and management. The continuous research and development efforts in this segment, with a focus on personalized medicine, are driving the growth of the respiratory diagnostics market.
“Hospitals and clinics end-user segment held the largest market share growing at the highest CAGR during the forecast period of the global respiratory diagnostics market.”
The rise in respiratory diseases, coupled with the growing awareness of the importance of early detection, has led to a surge in diagnostic procedures conducted in these facilities. The Hospitals and Clinics segment encompasses a wide range of diagnostic tools and services, including imaging studies, pulmonary function tests, and molecular diagnostics, providing a comprehensive approach to respiratory health assessment. By the increasing demand for respiratory diagnostic services in healthcare settings, where hospitals and clinics play a central role in disease diagnosis, management, and treatment, position this segment at the forefront of addressing the evolving challenges in respiratory diagnostics.
“North America to Witness Significant Growth From 2023 to 2029.”
Respiratory diagnostics market has been segmented into five major regional segments: North America, Europe, Asia Pacific, Latin America and Middle East and Africa. In 2022, the Asia Pacific region is anticipated to exhibit the highest compound annual growth rate (CAGR) during the forecast period. However, the North American market held the largest market share of the global market. North America stands as the frontrunner in the respiratory diagnostics market, commanding the largest market share throughout the forecast period. This leadership position is attributed to several factors, including a well-established healthcare infrastructure, high prevalence of respiratory diseases, and robust research and development activities in the region. The sophisticated diagnostic technologies available, coupled with a strong emphasis on early disease detection and management, contribute to the region’s dominance. Additionally, increased healthcare spending, a rising geriatric population, and growing awareness about respiratory health further propel market growth.
Breakdown of supply-side primary interviews: • By Company Type: Tier 1 – 35%, Tier 2 – 40%, and Tier 3 – 25% • By Designation: C-level – 30%, Director-level – 23%, and Others – 47% • By Region: North America – 35%, Europe – 20%, APAC – 25%, Latin America – 13%, Middle East & Africa – 7%
Some of the prominent players in the respiratory diagnostics market are Koninklijke Philips N.V. (Netherlands), BD (US), Abbott (US), Thermo Fisher Scientific Inc. (US), GE HealthCare (US), Bio-Rad Laboratories, Inc. (US), BioMérieux (France), Revvity, Inc. (US), Seegene Inc. (South Korea), Nihon Kohden Corporation (Japan), Vitalograph (UK), SDI Diagnostics (US), ResMed Inc. (US), Siemens Healthcare GmbH (Germany), Cosmed (Italy), Hologic, Inc. (US), Qiagen (Netherlands), Vyaire (US), Visby Medical, Inc (US), Briota Technologies Private Limited (India), Bird Healthcare (Australia), Löwenstein Medical Technology (Germany), ProAxsis (Northern Ireland), ndd Medical Technologies (US) and Compumedics Limited (Australia).
Research Coverage
This report studies respiratory diagnostics market based on products and services, test type, disease indication, end user, and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth. It analyzes the opportunities and challenges in the market and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five main regions and respective countries.
Reasons to Buy the Report
The report can help established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one or a combination of the below-mentioned five strategies.
This report provides insights into the following pointers:
• Analysis of key drivers (rising prevalence of respiratory diseases, Increasing incidence rate of preterm births, growing outbreaks of infectious diseases affecting the respiratory system, growing population with sleep disorders, rising R&D investments for technological advancement of medical devices), restraints (unfavorable reimbursement scenario for respiratory care diagnostics), opportunities (high respiratory diagnostics market growth opportunities in Asia Pacific and Latin America, improving POC diagnostics, growing awareness about the ill effects of untreated sleep apnea), and challenges (low awareness and lack of diagnosis of respiratory diseases) influencing the growth of respiratory diagnostics market.
• Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and product launches in respiratory diagnostics market.
• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various types of respiratory diagnostics across regions.
• Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in respiratory diagnostics market.
• Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in respiratory diagnostics market.
Table of Contents
1 INTRODUCTION 42
1.1 STUDY OBJECTIVES 42
1.2 MARKET DEFINITION 43
1.3 INCLUSIONS & EXCLUSIONS 43
1.4 MARKET SCOPE 44
1.4.1 MARKETS COVERED 44
1.4.2 REGIONS COVERED 45
1.4.3 YEARS CONSIDERED 45
1.4.4 CURRENCY CONSIDERED 46
1.5 STAKEHOLDERS 46
1.6 SUMMARY OF CHANGES 46
1.6.1 RECESSION IMPACT 47
2 RESEARCH METHODOLOGY 48
2.1 RESEARCH DATA 48
FIGURE 1 RESEARCH DESIGN 48
2.1.1 SECONDARY DATA 49
2.1.1.1 Key data from secondary sources 50
2.1.2 PRIMARY DATA 50
FIGURE 2 PRIMARY SOURCES 50
2.1.2.1 Key industry insights 51
2.1.2.2 Key data from primary sources 52
2.1.2.3 Breakdown of primary interviews 52
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 52
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY END USER, DESIGNATION, AND REGION 53
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 53
2.2 MARKET SIZE ESTIMATION 54
FIGURE 6 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 54
FIGURE 7 REVENUE SHARE ANALYSIS ILLUSTRATION: KONINKLIJKE PHILIPS N.V. 55
FIGURE 8 SUPPLY-SIDE ANALYSIS: RESPIRATORY DIAGNOSTICS MARKET (2022) 55
FIGURE 9 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 57
FIGURE 10 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 58
FIGURE 11 TOP-DOWN APPROACH 59
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 60
FIGURE 12 MARKET DATA TRIANGULATION METHODOLOGY 60
2.4 MARKET SHARE ESTIMATION 61
2.5 STUDY ASSUMPTIONS 61
2.6 RESEARCH LIMITATIONS 62
2.6.1 METHODOLOGY-RELATED LIMITATIONS 62
2.6.2 SCOPE-RELATED LIMITATIONS 62
2.7 RISK ASSESSMENT 62
TABLE 1 RISK ASSESSMENT: RESPIRATORY DIAGNOSTICS MARKET 62
2.8 IMPACT OF RECESSION ON RESPIRATORY DIAGNOSTICS MARKET 62
3 EXECUTIVE SUMMARY 63
FIGURE 13 RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2023 VS. 2029 (USD MILLION) 63
FIGURE 14 RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2023 VS. 2029 (USD MILLION) 64
FIGURE 15 RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2023 VS. 2029 (USD MILLION) 64
FIGURE 16 RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2023 VS. 2029 (USD MILLION) 65
FIGURE 17 GEOGRAPHICAL SNAPSHOT OF RESPIRATORY DIAGNOSTICS MARKET 66
4 PREMIUM INSIGHTS 67
4.1 RESPIRATORY DIAGNOSTICS MARKET OVERVIEW 67
FIGURE 18 TECHNOLOGICAL ADVANCEMENTS AND GROWTH IN GERIATRIC POPULATION TO DRIVE MARKET 67
4.2 GEOGRAPHICAL GROWTH OPPORTUNITIES: RESPIRATORY DIAGNOSTICS MARKET 68
FIGURE 19 NORTH AMERICA COMMANDED LARGEST MARKET SHARE IN 2022 68
4.3 REGIONAL MIX: RESPIRATORY DIAGNOSTICS MARKET 68
FIGURE 20 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 68
4.4 DEVELOPED VS. EMERGING ECONOMIES: RESPIRATORY DIAGNOSTICS MARKET, 2023 VS. 2029 (USD MILLION) 69
FIGURE 21 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH DURING STUDY PERIOD 69
5 MARKET OVERVIEW 70
5.1 INTRODUCTION 70
5.2 MARKET DYNAMICS 70
FIGURE 22 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES: RESPIRATORY DIAGNOSTICS MARKET 70
5.2.1 DRIVERS 71
5.2.1.1 Rising prevalence of respiratory diseases 71
5.2.1.1.1 Growth in global geriatric population 72
FIGURE 23 GLOBAL GERIATRIC POPULATION, BY REGION 72
5.2.1.1.2 Urbanization and growing pollution levels 72
FIGURE 24 PERCENTAGE OF DEATHS CAUSED BY HOUSEHOLD AND AMBIENT AIR POLLUTION, BY DISEASE (APPROXIMATELY, EVERY YEAR) 73
5.2.1.1.3 Rising prevalence of tobacco smoking 73
TABLE 2 PREVALENCE OF LIFESTYLE DISEASES AND RELATED DEATHS 73
5.2.1.1.4 Changing lifestyle, obesity, and physical inactivity 74
5.2.1.2 Increasing rate of preterm births 74
TABLE 3 TOP 10 COUNTRIES WITH HIGHEST NUMBER OF PRETERM BIRTHS, 2020 74
FIGURE 25 PRETERM BIRTH BY GESTATIONAL AGE AND REGION, 2020 75
5.2.1.3 Increasing outbreaks of infectious diseases affecting respiratory system 75
5.2.1.4 Growing population with sleep disorders 75
5.2.1.5 Rising R&D investments for technologically advanced medical devices 76
5.2.2 RESTRAINTS 76
5.2.2.1 Unfavorable reimbursement policies 76
5.2.2.2 Availability of low-cost products from local manufacturers 77
5.2.3 OPPORTUNITIES 77
5.2.3.1 Increased market growth in Asia Pacific and Latin America 77
5.2.3.2 Improving POC diagnostics 77
5.2.3.3 Increasing ill effects of untreated sleep apnea 78
TABLE 4 INITIATIVES TO PROMOTE AWARENESS ABOUT ILL EFFECTS OF UNTREATED SLEEP APNEA 78
5.2.4 CHALLENGES 79
5.2.4.1 Low awareness and lack of diagnosis of respiratory diseases 79
5.3 INDUSTRY TRENDS 80
5.3.1 RISING DEMAND FOR POINT-OF-CARE DIAGNOSTIC DEVICES 80
5.3.2 FOCUS OF MARKET PLAYERS ON GEOGRAPHICAL EXPANSIONS 80
5.3.3 INCREASING NUMBER OF REAGENT RENTAL AGREEMENTS 80
5.4 SUPPLY CHAIN ANALYSIS 81
FIGURE 26 SUPPLY CHAIN ANALYSIS: RESPIRATORY DIAGNOSTICS MARKET 82
5.5 TARIFF AND REGULATORY ANALYSIS 82
5.5.1 REGULATORY ANALYSIS 82
5.5.1.1 North America 82
5.5.1.1.1 US 82
TABLE 5 US: CLASSIFICATION OF MEDICAL EQUIPMENT 82
TABLE 6 US: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 83
5.5.1.1.2 Canada 83
TABLE 7 CANADA: LEVEL OF RISK, TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 83
5.5.1.2 Europe 84
TABLE 8 EUROPE: LEVEL OF RISK, TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 84
5.5.1.3 Asia Pacific 84
5.5.1.3.1 Japan 84
TABLE 9 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 85
5.5.1.3.2 China 85
TABLE 10 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 85
5.5.1.3.3 India 86
5.5.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 86
5.5.2.1 North America 86
TABLE 11 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 86
5.5.2.2 Europe 87
TABLE 12 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 87
5.5.2.3 Rest of the World 88
TABLE 13 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 88
5.6 ECOSYSTEM MARKET MAP 89
FIGURE 27 ECOSYSTEM MARKET MAP: RESPIRATORY DIAGNOSTICS MARKET 89
5.7 VALUE CHAIN ANALYSIS 90
FIGURE 28 VALUE CHAIN ANALYSIS: RESPIRATORY DIAGNOSTICS MARKET 91
5.8 TECHNOLOGY ANALYSIS 91
5.8.1 KEY TECHNOLOGIES 91
5.8.1.1 Digitalization of diagnostic tests 91
5.8.2 ADJACENT TECHNOLOGIES 92
5.8.2.1 Rapid respiratory diagnostic kits 92
5.8.3 COMPLEMENTARY TECHNOLOGIES 93
5.9 PATENT ANALYSIS 94
5.9.1 PATENT PUBLICATION TRENDS 94
FIGURE 29 PATENT PUBLICATION TRENDS, 2013–2023 94
5.9.2 JURISDICTION AND TOP APPLICANT ANALYSIS 94
FIGURE 30 TOP APPLICANTS AND OWNERS (COMPANIES/INSTITUTIONS) FOR RESPIRATORY DIAGNOSTIC PATENTS (JANUARY 2013–NOVEMBER 2023) 95
FIGURE 31 TOP APPLICANT COUNTRIES/REGIONS FOR RESPIRATORY DIAGNOSTIC PATENTS (JANUARY 2013–NOVEMBER 2023) 95
5.10 TRADE ANALYSIS 96
TABLE 14 TOP EXPORTERS OF RESPIRATORY DIAGNOSTICS DEVICES, 2022 (USD MILLION) 96
5.11 CASE STUDY ANALYSIS 97
TABLE 15 MONITORING OF COPD PATIENTS AT HOME 97
TABLE 16 REPLACEMENT PATTERN OF VENTILATORS IN DEVELOPED ECONOMIES VS. EMERGING ECONOMIES 97
TABLE 17 VOLUME DATA OF VENTILATORS, ICU VENTILATORS, PORTABLE VENTILATORS, PAP DEVICES, CPAP DEVICES, BIPAP DEVICES, AND SPIROMETERS 98
5.12 PORTER’S FIVE FORCES ANALYSIS 98
TABLE 18 PORTER’S FIVE FORCES ANALYSIS 98
5.12.1 THREAT OF NEW ENTRANTS 99
5.12.2 THREAT OF SUBSTITUTES 99
5.12.3 BARGAINING POWER OF SUPPLIERS 100
5.12.4 BARGAINING POWER OF BUYERS 100
5.12.5 INTENSITY OF COMPETITIVE RIVALRY 100
5.13 KEY CONFERENCES & EVENTS 100
TABLE 19 LIST OF KEY CONFERENCES & EVENTS IN 2023–2024 100
5.14 KEY STAKEHOLDERS & BUYING CRITERIA 101
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS 101
FIGURE 32 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR RESPIRATORY DIAGNOSTIC DEVICES 101
TABLE 20 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS 102
5.14.2 BUYING CRITERIA 102
FIGURE 33 KEY BUYING CRITERIA FOR RESPIRATORY DIAGNOSTIC DEVICES 102
TABLE 21 KEY BUYING CRITERIA FOR RESPIRATORY DIAGNOSTIC DEVICES 102
5.15 PRICING ANALYSIS 103
TABLE 22 AVERAGE SELLING PRICE OF RESPIRATORY DIAGNOSTIC DEVICES, BY PRODUCT TYPE (USD) 103
5.15.1 AVERAGE SELLING PRICE TREND, BY REGION 103
5.16 ADJACENT MARKETS 103
FIGURE 34 ADJACENT MARKETS OF RESPIRATORY DIAGNOSTICS MARKET 103
5.17 UNMET NEEDS IN RESPIRATORY DIAGNOSTIC DEVICES 104
5.18 USE OF ARTIFICIAL INTELLIGENCE IN RESPIRATORY DIAGNOSTICS MARKET 105
TABLE 23 USE OF ARTIFICIAL INTELLIGENCE IN RESPIRATORY DIAGNOSTICS MARKET 105
5.18.1 USE OF BIG DATA AND ARTIFICIAL INTELLIGENCE IN HEALTHCARE 105
5.19 REIMBURSEMENT SCENARIO ANALYSIS 106
TABLE 24 REIMBURSEMENT SCENARIO: RESPIRATORY DIAGNOSTICS MARKET 106
6 RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE 108
6.1 INTRODUCTION 109
TABLE 25 RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021–2029 (USD MILLION) 109
6.2 INSTRUMENTS AND DEVICES 109
6.2.1 INCREASING PREVALENCE OF RESPIRATORY DISEASES TO DRIVE MARKET 109
TABLE 26 RESPIRATORY DIAGNOSTICS MARKET FOR INSTRUMENTS AND DEVICES, BY COUNTRY, 2021–2029 (USD MILLION) 110
6.3 ASSAYS AND REAGENTS 110
6.3.1 RISING DEMAND FOR RESPIRATORY DIAGNOSTIC TEST KITS TO DRIVE MARKET 110
TABLE 27 RESPIRATORY DIAGNOSTICS MARKET FOR ASSAYS AND REAGENTS, BY COUNTRY, 2021–2029 (USD MILLION) 111
6.4 SERVICES AND SOFTWARE 111
6.4.1 INTRODUCTION TO ADVANCED AND AUTOMATED TECHNOLOGIES TO DRIVE MARKET 111
TABLE 28 RESPIRATORY DIAGNOSTICS MARKET FOR SERVICES & SOFTWARE, BY COUNTRY, 2021–2029 (USD MILLION) 112
7 RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE 113
7.1 INTRODUCTION 114
TABLE 29 RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION) 114
7.2 MECHANICAL TESTS 114
TABLE 30 RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY COUNTRY, 2021–2029 (USD MILLION) 115
TABLE 31 RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021–2029 (USD MILLION) 115
7.2.1 PULMONARY FUNCTION TESTS 116
TABLE 32 PULMONARY FUNCTION TESTS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 116
TABLE 33 PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021–2029 (USD MILLION) 117
7.2.2 SPIROMETRY 117
7.2.2.1 Spirometry to dominate pulmonary function tests segment during forecast period 117
TABLE 34 SPIROMETRY TESTS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 118
7.2.3 PEAK FLOW TESTS 118
7.2.3.1 Precise measurements from peak flow tests to help focus on effective treatment plans 118
TABLE 35 PEAK FLOW TESTS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 119
7.2.4 OBSTRUCTIVE SLEEP APNEA TESTS 119
7.2.4.1 Increased focus on diagnosis of sleep apnea at early stages to drive segment 119
TABLE 36 OBSTRUCTIVE SLEEP APNEA TESTS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 120
7.2.5 OTHER MECHANICAL TESTS 120
TABLE 37 OTHER MECHANICAL TESTS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 121
7.3 IMAGING TESTS 121
TABLE 38 RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY COUNTRY, 2021–2029 (USD MILLION) 122
TABLE 39 RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021–2029 (USD MILLION) 122
7.3.1 X-RAY 123
7.3.1.1 Increased investments in advanced radiographic technologies for superior lung imaging to drive segment 123
TABLE 40 X-RAY MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 123
7.3.2 COMPUTED TOMOGRAPHY 123
7.3.2.1 Growing focus on manufacturing high-resolution CT imaging for comprehensive respiratory assessments to drive segment 123
TABLE 41 COMPUTED TOMOGRAPHY MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 124
7.3.3 MAGNETIC RESONANCE IMAGING 124
7.3.3.1 Rising investments in AI-enhanced MRI analysis for precise respiratory assessment to drive segment 124
TABLE 42 MAGNETIC RESONANCE IMAGING MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 125
7.3.4 POSITRON EMISSION TOMOGRAPHY 125
7.3.4.1 Increased focus on effective treatment and management of lung cancer to drive segment 125
TABLE 43 POSITRON EMISSION TOMOGRAPHY MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 126
7.3.5 OTHER IMAGING TESTS 126
TABLE 44 OTHER IMAGING TESTS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 127
7.4 TRADITIONAL DIAGNOSTIC TESTS 127
TABLE 45 RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY COUNTRY, 2021–2029 (USD MILLION) 128
TABLE 46 RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021–2029 (USD MILLION) 128
7.4.1 IMMUNODIAGNOSTICS 129
7.4.1.1 Increased focus on rapid disease diagnosis to drive segment 129
TABLE 47 IMMUNODIAGNOSTICS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 129
7.4.2 BIOCHEMICAL CHARACTERIZATION 130
7.4.2.1 Rising number of collaborations among biochemical laboratories for developing advanced diagnostics to drive segment 130
TABLE 48 BIOCHEMICAL CHARACTERIZATION MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 130
7.4.3 MICROSCOPY 131
7.4.3.1 Lack of sensitivity toward emerging diseases and potential virus bioterrorism to limit market 131
TABLE 49 MICROSCOPY MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 131
7.5 MOLECULAR DIAGNOSTIC TESTS 132
TABLE 50 RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTIC TESTS, BY COUNTRY, 2021–2029 (USD MILLION) 132
TABLE 51 RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTIC TESTS, BY TYPE, 2021–2029 (USD MILLION) 133
7.5.1 PCR 133
7.5.1.1 Development of portable, real-time PCR machines and assays to drive segment 133
TABLE 52 PCR MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 134
7.5.2 NUCLEIC ACID AMPLIFICATION 134
7.5.2.1 Growing focus on automated nucleic acid amplification processes to drive segment 134
TABLE 53 NUCLEIC ACID AMPLIFICATION MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 135
7.5.3 IN SITU HYBRIDIZATION 135
7.5.3.1 Increased adoption of automated technologies for streamlined respiratory testing to drive segment 135
TABLE 54 IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 136
7.5.4 DNA SEQUENCING AND NEXT-GENERATION SEQUENCING 136
7.5.4.1 Rising number of research activities on sequencing-based biomarkers to drive segment 136
TABLE 55 DNA SEQUENCING AND NEXT GENERATION SEQUENCING MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 137
7.5.5 MICROARRAYS 137
7.5.5.1 Easy and effective detection of genetic signatures across multiple genes to drive segment 137
TABLE 56 MICROARRAYS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 138
7.5.6 OTHER MOLECULAR DIAGNOSTIC TESTS 138
TABLE 57 OTHER MOLECULAR DIAGNOSTIC TESTS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 139
8 RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION 140
8.1 INTRODUCTION 141
TABLE 58 RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021–2029 (USD MILLION) 141
8.2 TUBERCULOSIS 141
8.2.1 INCREASING EARLY SCREENING PROGRAMS AND FUNDS BY GOVERNMENT TO DRIVE MARKET 141
TABLE 59 RESPIRATORY DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY COUNTRY, 2021–2029 (USD MILLION) 142
8.3 ASTHMA 142
8.3.1 INCREASING AIR POLLUTION AND GROWING USE OF TOBACCO-BASED PRODUCTS TO DRIVE MARKET 142
TABLE 60 RESPIRATORY DIAGNOSTICS MARKET FOR ASTHMA, BY COUNTRY, 2021–2029 (USD MILLION) 143
8.4 LUNG CANCER 143
8.4.1 INCREASING NUMBER OF TOBACCO CONSUMERS TO DRIVE MARKET 143
TABLE 61 RESPIRATORY DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY, 2021–2029 (USD MILLION) 144
8.5 CHRONIC OBSTRUCTIVE PULMONARY DISEASE 144
8.5.1 INCREASED INVESTMENT IN RESEARCH GRANTS FOR NOVEL BIOMARKERS AND DIAGNOSTIC TECHNOLOGIES TO DRIVE MARKET 144
TABLE 62 RESPIRATORY DIAGNOSTICS MARKET FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE, BY COUNTRY, 2021–2029 (USD MILLION) 145
8.6 OTHER RESPIRATORY DISEASES 145
TABLE 63 RESPIRATORY DIAGNOSTICS MARKET FOR OTHER RESPIRATORY DISEASES, BY COUNTRY, 2021–2029 (USD MILLION) 146
9 RESPIRATORY DIAGNOSTICS MARKET, BY END USER 147
9.1 INTRODUCTION 148
TABLE 64 RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION) 148
9.2 HOSPITALS AND CLINICS 148
9.2.1 HOSPITALS AND CLINICS SEGMENT TO COMMAND LARGEST MARKET SHARE DURING STUDY PERIOD 148
TABLE 65 RESPIRATORY DIAGNOSTICS MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021–2029 (USD MILLION) 149
9.3 DIAGNOSTIC LABORATORIES 149
9.3.1 EASY AND AFFORDABLE TESTING PROCESSES WITH TIMELY AND ACCURATE RESULTS TO DRIVE MARKET 149
TABLE 66 RESPIRATORY DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2021–2029 (USD MILLION) 150
9.4 OTHER END USERS 150
TABLE 67 RESPIRATORY DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2029 (USD MILLION) 151
10 RESPIRATORY DIAGNOSTICS MARKET, BY REGION 152
10.1 INTRODUCTION 153
FIGURE 35 RESPIRATORY DIAGNOSTICS MARKET REGIONAL SNAPSHOT 153
TABLE 68 RESPIRATORY DIAGNOSTICS MARKET, BY REGION, 2021–2029 (USD MILLION) 154
10.2 NORTH AMERICA 155
FIGURE 36 NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET SNAPSHOT 155
TABLE 69 NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 156
TABLE 70 NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021–2029 (USD MILLION) 156
TABLE 71 NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION) 156
TABLE 72 NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021–2029 (USD MILLION) 157
TABLE 73 NORTH AMERICA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021–2029 (USD MILLION) 157
TABLE 74 NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021–2029 (USD MILLION) 157
TABLE 75 NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021–2029 (USD MILLION) 158
TABLE 76 NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021–2029 (USD MILLION) 158
TABLE 77 NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021–2029 (USD MILLION) 159
TABLE 78 NORTH AMERICA RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION) 159
10.2.1 NORTH AMERICA: RECESSION IMPACT 159
10.2.2 US 160
10.2.2.1 US to dominate North American respiratory diagnostics market during forecast period 160
TABLE 79 US: KEY MACROINDICATORS 160
TABLE 80 US: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021–2029 (USD MILLION) 161
TABLE 81 US: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION) 161
TABLE 82 US: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021–2029 (USD MILLION) 161
TABLE 83 US: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021–2029 (USD MILLION) 162
TABLE 84 US: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021–2029 (USD MILLION) 162
TABLE 85 US: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021–2029 (USD MILLION) 162
TABLE 86 US: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021–2029 (USD MILLION) 163
TABLE 87 US: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021–2029 (USD MILLION) 163
TABLE 88 US: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION) 164
10.2.3 CANADA 164
10.2.3.1 Growing geriatric population and increasing awareness about early diagnosis of respiratory diseases to drive market 164
TABLE 89 CANADA: COPD AND ASTHMA STATISTICS (2019 VS. 2020) 164
TABLE 90 CANADA: KEY MACROINDICATORS 165
TABLE 91 CANADA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021–2029 (USD MILLION) 165
TABLE 92 CANADA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION) 166
TABLE 93 CANADA: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021–2029 (USD MILLION) 166
TABLE 94 CANADA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021–2029 (USD MILLION) 166
TABLE 95 CANADA: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021–2029 (USD MILLION) 167
TABLE 96 CANADA: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021–2029 (USD MILLION) 167
TABLE 97 CANADA: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021–2029 (USD MILLION) 168
TABLE 98 CANADA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021–2029 (USD MILLION) 168
TABLE 99 CANADA: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION) 169
10.3 EUROPE 169
TABLE 100 EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 169
TABLE 101 EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021–2029 (USD MILLION) 170
TABLE 102 EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION) 170
TABLE 103 EUROPE: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021–2029 (USD MILLION) 170
TABLE 104 EUROPE: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021–2029 (USD MILLION) 171
TABLE 105 EUROPE: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021–2029 (USD MILLION) 171
TABLE 106 EUROPE: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021–2029 (USD MILLION) 171
TABLE 107 EUROPE: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021–2029 (USD MILLION) 172
TABLE 108 EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021–2029 (USD MILLION) 172
TABLE 109 EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION) 173
10.3.1 EUROPE: RECESSION IMPACT 173
10.3.2 GERMANY 173
10.3.2.1 Increasing public healthcare expenditure to drive market 173
TABLE 110 GERMANY: KEY MACROINDICATORS 174
TABLE 111 GERMANY: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021–2029 (USD MILLION) 174
TABLE 112 GERMANY: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION) 174
TABLE 113 GERMANY: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021–2029 (USD MILLION) 175
TABLE 114 GERMANY: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021–2029 (USD MILLION) 175
TABLE 115 GERMANY: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021–2029 (USD MILLION) 175
TABLE 116 GERMANY: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021–2029 (USD MILLION) 176
TABLE 117 GERMANY: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021–2029 (USD MILLION) 176
TABLE 118 GERMANY: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021–2029 (USD MILLION) 177
TABLE 119 GERMANY: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION) 177
10.3.3 FRANCE 177
10.3.3.1 Increasing prevalence of COPD and growing geriatric population to drive market 177
TABLE 120 FRANCE: KEY MACROINDICATORS 178
TABLE 121 FRANCE: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021–2029 (USD MILLION) 178
TABLE 122 FRANCE: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION) 178
TABLE 123 FRANCE: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021–2029 (USD MILLION) 179
TABLE 124 FRANCE: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021–2029 (USD MILLION) 179
TABLE 125 FRANCE: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021–2029 (USD MILLION) 179
TABLE 126 FRANCE: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021–2029 (USD MILLION) 180
TABLE 127 FRANCE: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021–2029 (USD MILLION) 180
TABLE 128 FRANCE: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021–2029 (USD MILLION) 181
TABLE 129 FRANCE: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION) 181
10.3.4 UK 181
10.3.4.1 Rising number of hospitals and increasing government funding to drive market 181
TABLE 130 UK: KEY MACROINDICATORS 182
TABLE 131 UK: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021–2029 (USD MILLION) 182
TABLE 132 UK: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION) 182
TABLE 133 UK: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021–2029 (USD MILLION) 183
TABLE 134 UK: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021–2029 (USD MILLION) 183
TABLE 135 UK: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021–2029 (USD MILLION) 183
TABLE 136 UK: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021–2029 (USD MILLION) 184
TABLE 137 UK: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021–2029 (USD MILLION) 184
TABLE 138 UK: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021–2029 (USD MILLION) 185
TABLE 139 UK: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION) 185
10.3.5 ITALY 185
10.3.5.1 Unfavorable reforms and reduction in healthcare expenditure by government to limit market 185
TABLE 140 ITALY: KEY MACROINDICATORS 186
TABLE 141 ITALY: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021–2029 (USD MILLION) 186
TABLE 142 ITALY: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION) 187
TABLE 143 ITALY: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021–2029 (USD MILLION) 187
TABLE 144 ITALY: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021–2029 (USD MILLION) 187
TABLE 145 ITALY: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021–2029 (USD MILLION) 188
TABLE 146 ITALY: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021–2029 (USD MILLION) 188
TABLE 147 ITALY: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021–2029 (USD MILLION) 189
TABLE 148 ITALY: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021–2029 (USD MILLION) 189
TABLE 149 ITALY: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION) 189
10.3.6 SPAIN 190
10.3.6.1 Increasing healthcare spending and growing demand for home care services to drive market 190
TABLE 150 SPAIN: KEY MACROINDICATORS 190
TABLE 151 SPAIN: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021–2029 (USD MILLION) 191
TABLE 152 SPAIN: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION) 191
TABLE 153 SPAIN: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021–2029 (USD MILLION) 191
TABLE 154 SPAIN: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021–2029 (USD MILLION) 192
TABLE 155 SPAIN: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021–2029 (USD MILLION) 192
TABLE 156 SPAIN: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021–2029 (USD MILLION) 192
TABLE 157 SPAIN: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021–2029 (USD MILLION) 193
TABLE 158 SPAIN: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021–2029 (USD MILLION) 193
TABLE 159 SPAIN: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION) 194
10.3.7 REST OF EUROPE 194
TABLE 160 REST OF EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021–2029 (USD MILLION) 194
TABLE 161 REST OF EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION) 195
TABLE 162 REST OF EUROPE: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021–2029 (USD MILLION) 195
TABLE 163 REST OF EUROPE: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021–2029 (USD MILLION) 195
TABLE 164 REST OF EUROPE: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021–2029 (USD MILLION) 196
TABLE 165 REST OF EUROPE: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021–2029 (USD MILLION) 196
TABLE 166 REST OF EUROPE: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021–2029 (USD MILLION) 197
TABLE 167 REST OF EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021–2029 (USD MILLION) 197
TABLE 168 REST OF EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION) 198
10.4 ASIA PACIFIC 198
FIGURE 37 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET SNAPSHOT 199
TABLE 169 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 200
TABLE 170 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021–2029 (USD MILLION) 200
TABLE 171 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION) 200
TABLE 172 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021–2029 (USD MILLION) 201
TABLE 173 ASIA PACIFIC: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021–2029 (USD MILLION) 201
TABLE 174 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021–2029 (USD MILLION) 201
TABLE 175 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021–2029 (USD MILLION) 202
TABLE 176 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021–2029 (USD MILLION) 202
TABLE 177 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021–2029 (USD MILLION) 203
TABLE 178 ASIA PACIFIC RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION) 203
10.4.1 ASIA PACIFIC: RECESSION IMPACT 203
10.4.2 JAPAN 204
10.4.2.1 Availability of universal healthcare reimbursement policy and growth in geriatric population to drive market 204
TABLE 179 JAPAN: KEY MACROINDICATORS 204
TABLE 180 JAPAN: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021–2029 (USD MILLION) 205
TABLE 181 JAPAN: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION) 205
TABLE 182 JAPAN: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021–2029 (USD MILLION) 205
TABLE 183 JAPAN: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021–2029 (USD MILLION) 206
TABLE 184 JAPAN: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021–2029 (USD MILLION) 206
TABLE 185 JAPAN: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021–2029 (USD MILLION) 206
TABLE 186 JAPAN: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021–2029 (USD MILLION) 207
TABLE 187 JAPAN: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021–2029 (USD MILLION) 207
TABLE 188 JAPAN RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION) 207
10.4.3 CHINA 208
10.4.3.1 Modern healthcare systems and improved reimbursement policies to drive market 208
TABLE 189 CHINA: KEY MACROINDICATORS 208
TABLE 190 CHINA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021–2029 (USD MILLION) 209
TABLE 191 CHINA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION) 209
TABLE 192 CHINA: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021–2029 (USD MILLION) 209
TABLE 193 CHINA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021–2029 (USD MILLION) 210
TABLE 194 CHINA: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021–2029 (USD MILLION) 210
TABLE 195 CHINA: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021–2029 (USD MILLION) 210
TABLE 196 CHINA: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021–2029 (USD MILLION) 211
TABLE 197 CHINA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021–2029 (USD MILLION) 211
TABLE 198 CHINA: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION) 212
10.4.4 INDIA 212
10.4.4.1 Large patient population and availability of skilled medical professionals to drive market 212
TABLE 199 INDIA: KEY MACROINDICATORS 212
TABLE 200 INDIA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021–2029 (USD MILLION) 213
TABLE 201 INDIA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION) 213
TABLE 202 INDIA: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021–2029 (USD MILLION) 213
TABLE 203 INDIA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021–2029 (USD MILLION) 214
TABLE 204 INDIA: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021–2029 (USD MILLION) 214
TABLE 205 INDIA: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021–2029 (USD MILLION) 214
TABLE 206 INDIA: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021–2029 (USD MILLION) 215
TABLE 207 INDIA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021–2029 (USD MILLION) 215
TABLE 208 INDIA: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION) 216
10.4.5 AUSTRALIA 216
10.4.5.1 Growing prevalence of chronic lung diseases to drive market 216
TABLE 209 AUSTRALIA: KEY MACROINDICATORS 216
TABLE 210 AUSTRALIA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021–2029 (USD MILLION) 217
TABLE 211 AUSTRALIA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION) 217
TABLE 212 AUSTRALIA: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021–2029 (USD MILLION) 217
TABLE 213 AUSTRALIA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021–2029 (USD MILLION) 218
TABLE 214 AUSTRALIA: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021–2029 (USD MILLION) 218
TABLE 215 AUSTRALIA: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021–2029 (USD MILLION) 218
TABLE 216 AUSTRALIA: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021–2029 (USD MILLION) 219
TABLE 217 AUSTRALIA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021–2029 (USD MILLION) 219
TABLE 218 AUSTRALIA RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION) 220
10.4.6 SOUTH KOREA 220
10.4.6.1 Increasing geriatric population and rising disposable income to drive market 220
TABLE 219 SOUTH KOREA: KEY MACROINDICATORS 220
TABLE 220 SOUTH KOREA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021–2029 (USD MILLION) 221
TABLE 221 SOUTH KOREA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION) 221
TABLE 222 SOUTH KOREA: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021–2029 (USD MILLION) 221
TABLE 223 SOUTH KOREA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021–2029 (USD MILLION) 222
TABLE 224 SOUTH KOREA: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021–2029 (USD MILLION) 222
TABLE 225 SOUTH KOREA: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021–2029 (USD MILLION) 222
TABLE 226 SOUTH KOREA: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021–2029 (USD MILLION) 223
TABLE 227 SOUTH KOREA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021–2029 (USD MILLION) 223
TABLE 228 SOUTH KOREA RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION) 224
10.4.7 REST OF ASIA PACIFIC 224
TABLE 229 REST OF ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021–2029 (USD MILLION) 224
TABLE 230 REST OF ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION) 225
TABLE 231 REST OF ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021–2029 (USD MILLION) 225
TABLE 232 REST OF ASIA PACIFIC: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021–2029 (USD MILLION) 225
TABLE 233 REST OF ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021–2029 (USD MILLION) 226
TABLE 234 REST OF ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021–2029 (USD MILLION) 226
TABLE 235 REST OF ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021–2029 (USD MILLION) 227
TABLE 236 REST OF ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021–2029 (USD MILLION) 227
TABLE 237 REST OF ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION) 228
10.5 LATIN AMERICA 228
TABLE 238 LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 228
TABLE 239 LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021–2029 (USD MILLION) 229
TABLE 240 LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION) 229
TABLE 241 LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021–2029 (USD MILLION) 229
TABLE 242 LATIN AMERICA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021–2029 (USD MILLION) 230
TABLE 243 LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021–2029 (USD MILLION) 230
TABLE 244 LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021–2029 (USD MILLION) 230
TABLE 245 LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021–2029 (USD MILLION) 231
TABLE 246 LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021–2029 (USD MILLION) 231
TABLE 247 LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION) 232
10.5.1 LATIN AMERICA: RECESSION IMPACT 232
10.5.2 BRAZIL 232
10.5.2.1 Favorable healthcare initiatives by government to drive market 232
TABLE 248 BRAZIL: KEY MACROINDICATORS 233
TABLE 249 BRAZIL: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021–2029 (USD MILLION) 233
TABLE 250 BRAZIL: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION) 233
TABLE 251 BRAZIL: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021–2029 (USD MILLION) 234
TABLE 252 BRAZIL: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021–2029 (USD MILLION) 234
TABLE 253 BRAZIL: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021–2029 (USD MILLION) 234
TABLE 254 BRAZIL: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021–2029 (USD MILLION) 235
TABLE 255 BRAZIL: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021–2029 (USD MILLION) 235
TABLE 256 BRAZIL: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021–2029 (USD MILLION) 236
TABLE 257 BRAZIL: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION) 236
10.5.3 MEXICO 236
10.5.3.1 Rising obesity rates and improving medical tourism to drive market 236
TABLE 258 MEXICO: KEY MACROINDICATORS 237
TABLE 259 MEXICO: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021–2029 (USD MILLION) 237
TABLE 260 MEXICO: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION) 237
TABLE 261 MEXICO: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021–2029 (USD MILLION) 238
TABLE 262 MEXICO: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021–2029 (USD MILLION) 238
TABLE 263 MEXICO: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021–2029 (USD MILLION) 238
TABLE 264 MEXICO: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021–2029 (USD MILLION) 239
TABLE 265 MEXICO: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021–2029 (USD MILLION) 239
TABLE 266 MEXICO: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021–2029 (USD MILLION) 240
TABLE 267 MEXICO: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION) 240
10.5.4 REST OF LATIN AMERICA 240
TABLE 268 REST OF LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021–2029 (USD MILLION) 241
TABLE 269 REST OF LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION) 241
TABLE 270 REST OF LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021–2029 (USD MILLION) 241
TABLE 271 REST OF LATIN AMERICA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021–2029 (USD MILLION) 242
TABLE 272 REST OF LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021–2029 (USD MILLION) 242
TABLE 273 REST OF LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021–2029 (USD MILLION) 242
TABLE 274 REST OF LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021–2029 (USD MILLION) 243
TABLE 275 REST OF LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021–2029 (USD MILLION) 243
TABLE 276 REST OF LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION) 244
10.6 MIDDLE EAST & AFRICA 244
10.6.1 GROWING PATIENT POPULATION AND INCREASING PENETRATION OF PRIVATE HEALTH INSURANCE COMPANIES TO DRIVE MARKET 244
TABLE 277 MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE, 2021–2029 (USD MILLION) 245
TABLE 278 MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2021–2029 (USD MILLION) 245
TABLE 279 MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2021–2029 (USD MILLION) 245
TABLE 280 MIDDLE EAST & AFRICA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2021–2029 (USD MILLION) 246
TABLE 281 MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2021–2029 (USD MILLION) 246
TABLE 282 MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2021–2029 (USD MILLION) 246
TABLE 283 MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR TESTS, BY TYPE, 2021–2029 (USD MILLION) 247
TABLE 284 MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE INDICATION, 2021–2029 (USD MILLION) 247
TABLE 285 MIDDLE EAST & AFRICA RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2021–2029 (USD MILLION) 248
10.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT 248
11 COMPETITIVE LANDSCAPE 249
11.1 OVERVIEW 249
11.2 KEY STRATEGIES/RIGHT TO WIN 249
TABLE 286 KEY STRATEGIES ADOPTED BY MAJOR PLAYERS IN RESPIRATORY DIAGNOSTICS MARKET 250
11.3 REVENUE SHARE ANALYSIS 251
FIGURE 38 RESPIRATORY DIAGNOSTICS REVENUE SHARE ANALYSIS FOR MECHANICAL, TRADITIONAL, AND MOLECULAR TESTS, BY KEY PLAYER, 2018–2022 (USD MILLION) 251
FIGURE 39 RESPIRATORY DIAGNOSTICS REVENUE SHARE ANALYSIS FOR IMAGING TESTS, BY KEY PLAYER, 2018–2022 (USD MILLION) 252
11.4 MARKET SHARE ANALYSIS 252
FIGURE 40 RESPIRATORY DIAGNOSTICS MARKET SHARE FOR MECHANICAL, TRADITIONAL, AND MOLECULAR TESTS, BY KEY PLAYER, 2022 252
FIGURE 41 RESPIRATORY DIAGNOSTICS MARKET SHARE ANALYSIS FOR IMAGING TESTS, BY KEY PLAYER, 2022 253
11.5 COMPANY EVALUATION MATRIX 253
11.5.1 STARS 253
11.5.2 EMERGING LEADERS 253
11.5.3 PERVASIVE PLAYERS 254
11.5.4 PARTICIPANTS 254
FIGURE 42 COMPANY EVALUATION MATRIX, 2022 254
11.5.5 COMPANY FOOTPRINT 255
TABLE 287 PRODUCT AND SERVICE FOOTPRINT 255
TABLE 288 TEST TYPE FOOTPRINT 256
TABLE 289 END USER FOOTPRINT 257
TABLE 290 REGIONAL FOOTPRINT 258
TABLE 291 OVERALL COMPANY FOOTPRINT 259
11.6 START-UP/SME EVALUATION MATRIX 260
11.6.1 PROGRESSIVE COMPANIES 260
11.6.2 RESPONSIVE COMPANIES 260
11.6.3 DYNAMIC COMPANIES 260
11.6.4 STARTING BLOCKS 260
FIGURE 43 START-UP/SME EVALUATION MATRIX, 2022 261
11.6.5 COMPETITIVE BENCHMARKING 262
11.7 COMPETITIVE SCENARIOS AND TRENDS 263
11.7.1 KEY PRODUCT LAUNCHES 263
TABLE 292 KEY PRODUCT LAUNCHES, 2021–2023 263
11.7.2 KEY DEALS 264
TABLE 293 KEY DEALS, 2021–2023 264
11.7.3 OTHER KEY DEVELOPMENTS 265
TABLE 294 OTHER KEY DEVELOPMENTS, 2021–2023 265
12 COMPANY PROFILES 266
12.1 KEY PLAYERS 266
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
12.1.1 KONINKLIJKE PHILIPS N.V. 266
TABLE 295 KONINKLIJKE PHILIPS N.V.: COMPANY OVERVIEW 266
FIGURE 44 KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT (2022) 267
12.1.2 BECTON, DICKINSON AND COMPANY 272
TABLE 296 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW 272
FIGURE 45 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2022) 273
12.1.3 ABBOTT 277
TABLE 297 ABBOTT: COMPANY OVERVIEW 277
FIGURE 46 ABBOTT: COMPANY SNAPSHOT (2022) 278
12.1.4 THERMO FISHER SCIENTIFIC INC. 280
TABLE 298 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 280
FIGURE 47 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022) 281
12.1.5 GE HEALTHCARE 285
TABLE 299 GE HEALTHCARE: COMPANY OVERVIEW 285
FIGURE 48 GE HEALTHCARE: COMPANY SNAPSHOT (2022) 286
12.1.6 BIO-RAD LABORATORIES, INC. 293
TABLE 300 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW 293
FIGURE 49 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2022) 294
12.1.7 BIOMÉRIEUX 298
TABLE 301 BIOMÉRIEUX: COMPANY OVERVIEW 298
FIGURE 50 BIOMÉRIEUX: COMPANY SNAPSHOT (2022) 299
12.1.8 REVVITY, INC. 301
TABLE 302 REVVITY, INC.: COMPANY OVERVIEW 301
FIGURE 51 PERKINELMER INC.: COMPANY SNAPSHOT (2022) 302
12.1.9 SEEGENE INC. 305
TABLE 303 SEEGENE INC.: COMPANY OVERVIEW 305
FIGURE 52 SEEGENE INC.: COMPANY SNAPSHOT (2022) 305
12.1.10 NIHON KOHDEN CORPORATION 310
TABLE 304 NIHON KOHDEN CORPORATION: COMPANY OVERVIEW 310
FIGURE 53 NIHON KOHDEN CORPORATION: COMPANY SNAPSHOT (2022) 311
12.1.11 VITALOGRAPH 313
TABLE 305 VITALOGRAPH: COMPANY OVERVIEW 313
12.1.12 SDI DIAGNOSTICS 315
TABLE 306 SDI DIAGNOSTICS: COMPANY OVERVIEW 315
12.1.13 RESMED 317
TABLE 307 RESMED: COMPANY OVERVIEW 317
FIGURE 54 RESMED: COMPANY SNAPSHOT (2022) 318
12.1.14 SIEMENS HEALTHCARE GMBH 320
TABLE 308 SIEMENS HEALTHCARE GMBH: COMPANY OVERVIEW 320
FIGURE 55 SIEMENS HEALTHCARE GMBH: COMPANY SNAPSHOT (2022) 320
12.1.15 COSMED SRL 325
TABLE 309 COSMED SRL: COMPANY OVERVIEW 325
12.1.16 HOLOGIC, INC. 327
TABLE 310 HOLOGIC, INC.: COMPANY OVERVIEW 327
FIGURE 56 HOLOGIC, INC.: COMPANY SNAPSHOT (2022) 328
12.1.17 QIAGEN 331
TABLE 311 QIAGEN: COMPANY OVERVIEW 331
FIGURE 57 QIAGEN: COMPANY SNAPSHOT (2022) 331
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
12.2 OTHER PLAYERS 336
12.2.1 VYAIRE MEDICAL, INC. 336
12.2.2 VISBY MEDICAL, INC. 337
12.2.3 BRIOTA TECHNOLOGIES PVT. LTD. 337
12.2.4 BIRD HEALTHCARE 338
12.2.5 LÖWENSTEIN MEDICAL TECHNOLOGY GMBH 339
12.2.6 PROAXSIS 339
12.2.7 NDD MEDICAL TECHNOLOGIES 340
12.2.8 COMPUMEDICS LIMITED 341
13 APPENDIX 342
13.1 DISCUSSION GUIDE 342
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 347
13.3 CUSTOMIZATION OPTIONS 349
13.4 RELATED REPORTS 349
13.5 AUTHOR DETAILS 350